scholarly journals Women’s Ischemic Syndrome Evaluation

Circulation ◽  
2004 ◽  
Vol 109 (6) ◽  
Author(s):  
Leslee J. Shaw ◽  
Jannet F. Lewis ◽  
Mark A. Hlatky ◽  
Willa A. Hsueh ◽  
Sheryl F. Kelsey ◽  
...  
Keyword(s):  
Ischemic Syndrome

scholarly journals Women’s Ischemic Syndrome Evaluation

Circulation ◽  
2004 ◽  
Vol 109 (6) ◽  
pp. 805-807 ◽  
Author(s):  
Noel Bairey Merz ◽  
Robert O. Bonow ◽  
George Sopko ◽  
Robert S. Balaban ◽  
Richard O. Cannon ◽  
...  
Keyword(s):  
Ischemic Syndrome

Telodiencephalic Ischemic Syndrome

1987 ◽  
Vol 44 (12) ◽  
pp. 1218-1219 ◽  
Author(s):  
R. Schiffter
Keyword(s):  
Ischemic Syndrome

scholarly journals Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma

2022 ◽  
Vol 74 (1) ◽  
pp. 27-33
Author(s):  
Naris Kitnarong ◽  
Janyawassamon Kittipiriyakul ◽  
Anuwat Jiravarnsirikul
Keyword(s):  
Neovascular Glaucoma ◽  
Additional Treatment ◽  
Adjunctive Treatment ◽  
Panretinal Photocoagulation ◽  
Vein Occlusion ◽  
Corrected Visual Acuity ◽  
Intravitreal Aflibercept ◽  
The One ◽  
Ischemic Syndrome

Objective: To investigate intravitreal aflibercept (IVA) injection as an adjunctive treatment to trabeculectomy with mitomycin C (TMC) and panretinal photocoagulation (PRP) for neovascular glaucoma (NVG).Materials and Methods: PRP and IVA (2 mg/0.05 ml) injection were given, and TMC was performed within 2weeks after IVA. Additional PRP, laser suture lysis, subconjunctival 5-fluorouracil injection, and bleb needlingwere performed after TMC if indicated. Best corrected visual acuity (BCVA), intraocular pressure (IOP), surgicalcomplications, and number of anti-glaucoma medications were collected.Results: Five eyes from 5 consecutive patients were included. Two eyes had proliferative diabetic retinopathy (PDR), 2 central retinal vein occlusion, and 1 ocular ischemic syndrome (OIS) (mean initial IOP: 46.8±6.8 mmHg). NVI regression occurred in one eye after PRP alone, and in one eye after PRP and IVA resulting in a good IOP control with topical medical therapy. The other 3 underwent TMC. The preoperative IOP was 34 (OIS), 54 (PDR), and 50 (PDR) mmHg. The 3-month postoperative IOP decreased to 8, 8, and 4 mmHg, respectively, and to 21, 10, and 6 mmHg, respectively, at the last visit. Only the one OIS eye required postoperative topical IOP-lowering medications. Final BCVA was improved, unchanged, and decreased in 2, 2, and 1 eye, respectively. No intraoperative/postoperative complications or NVI recurrence were observed (mean follow-up: 10.7 months).Conclusion: Intravitreal aflibercept was shown to be a potentially effective additional treatment to PRP and TMC in patients with NVG.

Sign in / Sign up

Export Citation Format

Share Document